GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Voorraadrapport

Marktkapitalisatie: ₹409.1b

GlaxoSmithKline Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

GlaxoSmithKline Pharmaceuticals heeft een totaal eigen vermogen van ₹16.7B en een totale schuld van ₹0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk ₹37.5B en ₹20.7B. De EBIT GlaxoSmithKline Pharmaceuticals is ₹9.6B waardoor de rentedekking -13.5 is. Het heeft contanten en kortetermijnbeleggingen van ₹21.1B.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

₹0

Schuld

Rente dekkingsratio-13.5x
Contant₹21.11b
Aandelen₹16.73b
Totaal verplichtingen₹20.73b
Totaal activa₹37.46b

Recente financiële gezondheidsupdates

Recent updates

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 01
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹30.1B ) GLAXO } overtreffen de korte termijn passiva ( ₹18.1B ).

Langlopende schulden: De kortetermijnactiva GLAXO ( ₹30.1B ) overtreffen de langetermijnschulden ( ₹2.6B ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GLAXO is schuldenvrij.

Schuld verminderen: GLAXO heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 0.01% was.

Schuldendekking: GLAXO heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: GLAXO heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven